» Articles » PMID: 21248069

Intragenic Rearrangement and Altered RNA Splicing of the Androgen Receptor in a Cell-based Model of Prostate Cancer Progression

Overview
Journal Cancer Res
Specialty Oncology
Date 2011 Jan 21
PMID 21248069
Citations 126
Authors
Affiliations
Soon will be listed here.
Abstract

Androgen depletion for advanced prostate cancer (PCa) targets activity of the androgen receptor (AR), a steroid receptor transcription factor required for PCa growth. The emergence of lethal castration-resistant PCa (CRPCa) is marked by aberrant reactivation of the AR despite ongoing androgen depletion. Recently, alternative splicing has been described as a mechanism giving rise to COOH-terminally truncated, constitutively active AR isoforms that can support the CRPCa phenotype. However, the pathologic origin of these truncated AR isoforms is unknown. The goal of this study was to investigate alterations in AR expression arising in a cell-based model of PCa progression driven by truncated AR isoform activity. We show that stable, high-level expression of truncated AR isoforms in 22Rv1 CRPCa cells is associated with intragenic rearrangement of an approximately 35-kb AR genomic segment harboring a cluster of previously described alternative AR exons. Analysis of genomic data from clinical specimens indicated that related AR intragenic copy number alterations occurred in CRPCa in the context of AR amplification. Cloning of the break fusion junction in 22Rv1 cells revealed long interspersed nuclear elements (LINE-1) flanking the rearranged segment and a DNA repair signature consistent with microhomology-mediated, break-induced replication. This rearrangement served as a marker for the emergence of a rare subpopulation of CRPCa cells expressing high levels of truncated AR isoforms during PCa progression in vitro. Together, these data provide the first report of AR intragenic rearrangements in CRPCa and an association with pathologic expression of truncated AR isoforms in a cell-based model of PCa progression.

Citing Articles

Comparative transcriptomics reveals a mixed basal, club, and hillock epithelial cell identity in castration-resistant prostate cancer.

Pitzen S, Rudenick A, Qiu Y, Zhang W, Munro S, McCluskey B Proc Natl Acad Sci U S A. 2025; 122(6):e2415308122.

PMID: 39913208 PMC: 11831193. DOI: 10.1073/pnas.2415308122.


AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients.

Knutson T, Luo B, Kobilka A, Lyman J, Guo S, Munro S Nat Commun. 2024; 15(1):10648.

PMID: 39663356 PMC: 11634963. DOI: 10.1038/s41467-024-54847-1.


Selective killing of castration-resistant prostate cancer cells by formycin A via the ATF4-CHOP axis.

Takei T, Hamamura Y, Hongo H, Tashiro E, Imoto M, Kosaka T Cancer Sci. 2024; 115(12):3997-4007.

PMID: 39327674 PMC: 11611774. DOI: 10.1111/cas.16349.


Targeting the CLK2/SRSF9 splicing axis in prostate cancer leads to decreased ARV7 expression.

Van Goubergen J, Perina M, Handle F, Morales E, Kremer A, Schmidt O Mol Oncol. 2024; 19(2):496-518.

PMID: 39258426 PMC: 11792998. DOI: 10.1002/1878-0261.13728.


CDK9 inhibition inhibits multiple oncogenic transcriptional and epigenetic pathways in prostate cancer.

Rahman R, Rahaman M, Hanson A, Choo N, Xie J, Townley S Br J Cancer. 2024; 131(6):1092-1105.

PMID: 39117800 PMC: 11405875. DOI: 10.1038/s41416-024-02810-8.


References
1.
Hyytinen E, Haapala K, Thompson J, Lappalainen I, Roiha M, Rantala I . Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Lab Invest. 2002; 82(11):1591-8. DOI: 10.1097/01.lab.0000038924.67707.75. View

2.
Culig Z, Bartsch G . Androgen axis in prostate cancer. J Cell Biochem. 2006; 99(2):373-81. DOI: 10.1002/jcb.20898. View

3.
Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C . In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995; 9(4):401-6. DOI: 10.1038/ng0495-401. View

4.
Cordaux R, Batzer M . The impact of retrotransposons on human genome evolution. Nat Rev Genet. 2009; 10(10):691-703. PMC: 2884099. DOI: 10.1038/nrg2640. View

5.
Dehm S, Tindall D . Regulation of androgen receptor signaling in prostate cancer. Expert Rev Anticancer Ther. 2005; 5(1):63-74. DOI: 10.1586/14737140.5.1.63. View